StroMedix Lands $25,000,000 Series B Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    One Canal Park Cambridge, MA 02142
  • Company Description
    Stromedix is a clinical-stage biotechnology company committed to developing novel drugs to treat fibrotic organ failure. Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer. The company plans to build its pipeline through both internal drug discovery and in-licensing.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Earlier this year, Stromedix initiated a Phase 1 clinical trial of STX-100, the Company’s lead drug candidate. STX-100 is a novel humanized monoclonal antibody licensed in 2007 from Biogen Idec, which is also a shareholder in the company.
  • M&A Terms
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Bessemer Venture Partners
  • Venture Investor
    Red Abbey Venture Partners
  • Venture Investor
    Atlas Venture
  • Venture Investor
    Frazier Healthcare Ventures

Trending on Xconomy